CBIO - NASDAQ
Crescent Biopharma, Inc.
$17.95
+5.6%Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotCrescent Biopharma, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Crescent Biopharma, Inc. Cash Flow Statement
CBIO • NASDAQ
| Crescent Biopharma, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-149.9M | -37.9M | -36.9M | -46.7M | -63.4M | -51M | -57.9M | -48.3M | -33.3M | -31.8M | -12.8M | -11.1M | -10.6M | 3.7M | -6.1M | |
84K | 35.2K | 153.3K | 207.1K | 264.6K | 270.8K | 279.2K | 275.1K | 263.5K | 190.5K | 191.5K | 158.7K | 133.1K | 99.9K | 83.9K | |
0.0 | 0.0 | 0.0 | 0.0 | 2.2K | 0.0 | 0.0 | 0.0 | 0.0 | -3M | -2.3M | 0.0 | -425.7K | -415.2K | 0.0 | |
13.3M | 4.8M | 3.6M | 3.9M | 6.1M | 6.9M | 6.2M | 4.6M | 3.8M | 3M | 2.3M | 1.6M | 425.7K | 415.2K | 376.2K | |
78.4M | 814.5K | 864.9K | 828.5K | 749K | 680.8K | 620.1K | 168.0 | 3.2M | 3M | 2.3M | 1.4K | 425.7K | 415.2K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (80K) | (0.0) | (0.0) | (0.0) | |
-13.4M | 1.2M | -2.6M | -4.7M | -1.2M | 3.9M | -1.2M | 80.1K | -511.6K | -1.1M | 2M | 5M | -5.5M | -14.6M | 19.5M | |
-71.5M | -31.1M | -34.9M | -46.5M | -57.5M | -39.2M | -52M | -43.3M | -29.8M | -29.7M | -8.2M | -4.3M | -15.5M | -10.5M | 13.9M | |
INVESTING ACTIVITIES | |||||||||||||||
-919K | -10K | -21.4K | -84.2K | -14.9K | -68.5K | -144.9K | -125.6K | -294.1K | -704.2K | -268.6K | -212.6K | -82.1K | -316.2K | -182.4K | |
(0.0) | (30K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-72M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -126K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -10K | -57.7K | |
-72.9M | (20K) | -21.4K | -84.2K | -14.9K | -68.5K | -144.9K | -125.6K | -294.1K | -704.2K | -268.6K | -212.6K | -82.1K | -326.2K | -240.1K | |
FINANCING ACTIVITIES | |||||||||||||||
-172K | 5.4K | 28.7M | 4.2M | 10.7M | 17.8M | 0.0 | 128.4M | 113.6M | 23.6M | 0.0 | 57.2M | 558.9K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -24.2K | |
-177K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
323.2M | 0.0 | 116.5K | 0.0 | 25K | 319.3K | 412.9K | 1M | 373.4K | 72.6K | 114.1K | 134.3K | 0.0 | 237.0 | 0.0 | |
323M | 5.4K | 28.8M | 4.2M | 10.7M | 18.1M | 412.9K | 129.4M | 113.9M | 23.7M | 114.1K | 57.4M | 558.9K | 237.0 | -24.2K | |
CASH FLOW SUMMARY | |||||||||||||||
178.5M | -31.1M | -6.1M | -42.4M | -46.8M | -21.2M | -51.7M | 86M | 83.9M | -6.8M | -8.4M | 52.9M | -15.1M | -10.8M | 13.6M | |
34.8M | 41.8M | 47.9M | 90.3M | 137M | 158.2M | 209.9M | 123.9M | 40M | 46.8M | 55.2M | 2.3M | 17.4M | 28.2M | 14.6M | |
213.3M | 10.7M | 41.8M | 47.9M | 90.3M | 137M | 158.2M | 209.9M | 123.9M | 40M | 46.8M | 55.2M | 2.3M | 17.4M | 28.2M | |
-72.5M | -31.1M | -34.9M | -46.5M | -57.5M | -39.3M | -52.1M | -43.5M | -30.1M | -30.4M | -8.5M | -4.5M | -15.6M | -10.8M | 13.7M |
SEC Filings
CBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
S-1 S-1 N/A | January 07, 2026 | January 07, 2026 | ||
8-K 8-K 2025 N/A | December 04, 2025 | December 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your CBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.